*together with Vantage Point
Are you tired of trading “alone in a hole?” See JW’s invitation below and join us any time (FREE) in the Market Masters Room. Emerge from isolation and make some new friends 👬.
FOCUS LIST🔎
BPTH – Up over 50% in the pre-market after reporting solid tumor patient response supporting BP1001-A’s compelling potential as treatment for advanced solid tumors
WENA – Up over 30% in pre after acquiring license to needle-free dry powder autoinjector from Transfertech Sherbrooke
VEV – Up over 25% in pre after entering into workout agreement to develop a restructuring plan with creditors
*together with Vantage Point
Don’t Wait: Add AI to Your Trading Tool Belt ASAP!!!
HOTLIST🔥
BPTH – Up over 50% in the pre-market after reporting solid tumor patient response supporting BP1001-A’s compelling potential as treatment for advanced solid tumors
Bio-Path Holdings Inc. (BPTH) operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States.
In the pre-market this morning, the company provided an update from its ongoing Phase 1/1b clinical trial of BP1001-A in solid tumor patients and reports continued patient progress from the Company’s ongoing Phase 2 triple combination study of prexigebersen in Acute Myeloid Leukemia (AML).
Highlights include:
First Solid Tumor Patient Treated with Second, Higher Dose in Phase 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued Stable Disease
Reports Continued Patient Progress from Phase 2 Triple Combination Study of Prexigebersen in Acute Myeloid Leukemia (AML)
Supportive Safety and Efficacy Data from Two Assets Validate Potential of DNAbilize® Platform Technology to Treat Most Vulnerable Cancer Patients
Peter H. Nielsen, President and Chief Executive Officer of Bio-Path stated:
“These positive responses mark a significant milestone for Bio-Path as they suggest our DNAbilize platform technology has the potential to produce multiple drug candidates capable of target-specific protein inhibition for over-expressed, disease-causing gene products,”
The stock traded up over 50% in the pre-market in reaction to the positive results.
The $1.90 area acted as support in the pre-market and will be an important level to watch.
Above it, targets to the upside are $2.20, $2.48, $2.60, $3.20 and then the pre-market high at $3.43.
Below $1.90, targets to the downside are $1.70, $1.59 and then a gap fill at $1.48 with $1.40 below that.
👉 Are you interested in learning more about trading?
👉 Have you ever wondered about trading options but don’t know where to start?
👉 Are you a seasoned pro but tired of trading alone in a hole with no one to celebrate with you when things go well or commensurate with you when they don’t?
I’m your man…
… and Market Navigator is YOUR service!
WENA – Up over 30% in pre after acquiring license to needle-free dry powder autoinjector from Transfertech Sherbrooke
Anew Medical Inc. (WENA) is a biopharmaceutical company that develops therapies for neurological and age-related disorders, and specialty diagnostics.
In the pre-market this morning, the company announced the signing of an exclusive worldwide license agreement with Transfertech Sherbrooke (“TTS”) regarding Nanoject, a needle-free, freeze-dried nanopowder autoinjector for medicines and vaccines.
Needle phobia and injection or blood-drawing anxiety are prevalent among adults and children, creating barriers to adhering to doctor visits and medication protocols. Alternatives to needle/syringes have been introduced including creams, patches, inhalers, liquid autoinjectors, but they have significant cost and formulation limitations for topical applications.
The patented Nanoject core delivery device exploits the pressure-driven flow generated by the triggering of a miniature shock tube to “shoot” nano-sized or micron-sized particles of medicine (drugs, proteins, DNA, RNA) at high speed (600 meters/second) into the skin for intradermal and subcutaneous tissue delivery.
WENA traded up over 30% in the pre-market in reaction to the news.
The $1.26 area has acted as support in the pre-market and will be an important level to watch.
Above it, targets to the upside are $1.40, $1.60, $1.80 and then the pre-market high at $1.98. Beyond that, $2.50 and $3 come into play.
Below $1.26, targets to the downside are $1.10 and then a gap fill at $1.03.
VEV – Up over 25% in pre after entering into workout agreement to develop a restructuring plan with creditors
Vicinity Motor Corp. (VEV) designs, builds, and distributes a suite of transit buses for public and commercial use under the Vicinity brand in the United States and Canada. It offers electric, CNG, and clean diesel buses, as well as electric trucks and spare parts.
In the pre-market this morning, the company announced it has reached an agreement with its secured lenders to execute a workout and financial restructuring plan to address the previously announced demands from Royal Bank of Canada and Export Development Canada (the “Secured Lenders”) in respect of outstanding credit facilities to progress towards financial stability for the Company.
Vicinity and the Secured Lenders have agreed to the terms of the workout for the next 60 days, discussing with the Secured Lenders its revenues, debt structures, and initiatives to reorganize. During this period, the Company will return to limited operations and the Secured Lenders will retain all rights previously asserted. Prior to the conclusion of the workout period, Vicinity expects to have entered into a restructuring plan that may include agreements for payment and creditor rights and protections.
During this period Vicinity will work to preserve the value of its assets, execute in process deliveries, and facilitate technical and parts support programs. The Company will continue to work closely with vendors, customers, and partners during this period as it endeavors to return to normal full operations within the 60-day period.
Brent Phillips, President of Vicinity Motor Corp. stated:
“Our strong backlog of fuel neutral bus orders, including clean diesel and electric buses, provides a solid foundation for this workout plan. The market opportunity for Vicinity buses and industry metrics support accelerated development of our energy efficient transit bus product line while the Class 3 commercial truck market continues to develop.”
The stock traded up over 25% in the pre-market in reaction to the news.
The $0.18 area acted as support in the pre-market and will be an important level to watch.
Above it, targets to the upside are $0.20, $0.22, $0.26 and then the pre-market high at $0.2999.
Below $0.18, targets to the downside are $0.16 and then a gap fill at $0.1501 with $0.10 below that.
MARKET NEWS 📰
P.S. Make sure you text “RAGE” to (888) 404-5747 to get all of our latest HOT STOCK ideas!
Questions or concerns about our products? Email Support@360wallstreet.io © Copyright 2022, RagingBull
DISCLAIMER: To more fully understand any Ragingbull.com, LLC (“RagingBull”) subscription, website, application or other service (“Services”), please review our full disclaimer located at https://ragingbull.com/disclaimer
FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision.
RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers’ trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment.
RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers.
RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled.
*Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals.
WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.
